Abstract:
Cerebrovascular pathology has evolved from a medical concern to a social issue, with
the efficacy of secondary neuroprotection remaining a pertinent question. While some
investigations have been conducted to elucidate the effectiveness of a comprehensively
grounded pharmacological correction scheme under conditions of experimentaly induced
chronic brain ischemia, further refinement is necessary to understand the behavioral effects of
animals, dosages, routes of administration of pharmacological agents, and analysis of obtained
data. The aim of this study was to assess the effectiveness of applying Semax and hopantenic
acid in the comprehensive treatment of motor disorders and established neurological
impairments in rats with experimentally induced chronic brain ischemia. We determined that
rats with chronic brain ischemia exhibit muscular dysfunctions and experience pronounced
disturbances in emotional behavior from the first day. It has been demonstrated that the
separate and combined application of Semax and hopantenic acid contributes to the restoration
of muscle activity, normalization of coordination, and emotional behavior in rats with chronic brain ischemia. The most significant neuroprotective effect in rats with chronic brain ischemia
was observed with the combined administration of Semax and hopantenic acid, starting from
the 3rd day of the trial. The subsequent in the series of anti-ischemic effectiveness is the impact
of Semax from the 3rd day of the experiment. The least pronounced neuroprotective effect was
exhibited by hopantenic acid, starting from the 5th day of the experiment. We consider these
findings to be an experimental foundation supporting the feasibility of clinically testing the
effects of combined Semax and hopantenic acid administration, capable of restoring functional
disorders caused by chronic brain ischemia. In conclusion, the observed effectiveness of the
developed pathogenetically justified complex for the correction of post-ischemic muscle
dysfunction and disorders indicates the development of an anti-ischemic effect, as well as the
fundamental possibility of improving the treatment for patients with chronic brain ischemia
through clinical intranasal administration of Semax, either alone or in combination with
hopantenic acid. However, for a more comprehensive understanding of the temporal and dosedependent effects of this complex pathogenetic correction scheme on other disorders and
dysfunctions related to chronic brain ischemia and to formulate final conclusions, it is
essential to conduct separate series of experimental studies.
